Enliven Therapeutics (ELVN) officer-director discloses no owned securities

Rhea-AI Filing Summary

Enliven Therapeutics, Inc. reported that an individual serving as its President, CEO and Director has no beneficial ownership of the company’s securities as of 12/11/2025. Filed pursuant to Section 16(a) of the Exchange Act, the report indicates that this person does not hold any non-derivative or derivative securities of Enliven Therapeutics despite their leadership and board roles.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Fair Richard A.

(Last) (First) (Middle)

C/O ENLIVEN THERAPEUTICS, INC.

6200 LOOKOUT ROAD

(Street)

BOULDER CO 80301

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
12/11/2025

3. Issuer Name and Ticker or Trading Symbol
Enliven Therapeutics, Inc. [ ELVN ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT AND CEO

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24.1 - Power of Attorney

No securities are beneficially owned.

	/s/ Ben Hohl, by power of attorney	12/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does this ownership report show for Enliven Therapeutics (ELVN)?

The report shows that a person associated with Enliven Therapeutics, Inc. has no securities beneficially owned, as stated in the remarks section.

What roles does the reporting person hold at Enliven Therapeutics (ELVN)?

The reporting person is identified as both a Director and an Officer, with the officer title given as President and CEO of Enliven Therapeutics, Inc.

As of what date is the beneficial ownership information reported for ELVN?

The date of the event requiring the statement is listed as 12/11/2025, which is the reference date for the ownership information.

Does the reporting person own any Enliven Therapeutics stock or derivative securities?

No. The remarks explicitly state, "No securities are beneficially owned", and the non-derivative and derivative securities tables contain no reported holdings.

Under which regulations was this Enliven Therapeutics ownership report submitted?

The report is filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940, as indicated in the heading.

Is this ownership report filed by a single person or multiple reporting persons for ELVN?

The document indicates that it is a Form filed by One Reporting Person, rather than by more than one reporting person.